Sandoz, announces that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis
Novartis confirmed plans for the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023
Sandoz has announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar...
The Sandoz application for a marketing authorisation at EMA for Zioxtenzo (pegfilgrastim biosimilar) has been withdrawn. Zioxtenzo was developed as...
Sandoz announced that the FDA has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar...
Sandoz announced that the FDA has accepted its Biologics License Application (BLA) under the 351(k) pathway for its proposed biosimilar...
Sandoz, a global leader in generic pharmaceuticals and biosimilars, announced that the citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.
Sandoz, a Novartis division and the pioneer and global leader in biosimilars, announced that the FDA approved its biosimilar, Hyrimoz...
Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off